Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Neurotransmitter may help aggressive prostate cancer shut out immune cells from the start (opens in a new tab)

medicalxpress.com · 2026-09-25

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

One claim goes further than the study.

  • 4 supported
  • 1 overstated

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

One claim overstates the study. Four of five check out.

  • 4 supported
  • 1 overstated
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedIn a mouse model, researchers found excessive NMU in tissue cells before cancer developed, and they said NMU-activated neutrophils suppress T cells and prevent T-cell migration to the prostate.View evidenceHide evidence

Why this verdict

The mouse-model and neutrophil/T-cell suppression components are broadly supported: early NEPC shows NMU upregulation and altered immune infiltration, and NMU-treated PMNs suppress T-cell proliferation. However, the abstract-level profile does not establish that excessive NMU was present 'before cancer developed,' nor does it directly show that NMU-activated neutrophils 'prevent T-cell migration to the prostate' as a fully demonstrated causal step. Those details outrun the abstract evidence.

1

Study evidence

Early-stage NEPC in a transgenic mouse model is associated with increased intraprostatic Ly6G+ PMN recruitment.

“Using a transgenic mouse model, we now show that early stages of NEPC are associated with increased intraprostatic recruitment of Ly6G+ polymorphonuclear neutrophils (PMN) and reduced infiltration of CD8+ T cells.”
2

Study evidence

Early NEPC in the transgenic mouse model was associated with increased intraprostatic Ly6G+ polymorphonuclear neutrophils (PMN) and reduced CD8+ T cell infiltration.

“This coincided with expansive transcriptional changes of increased cell viability and cell migration, as well as upregulation of multiple neuronal mediators with the neuropeptide, Neuromedin U (NMU) as the top hit (Z score = 4.34; FDR < 5%; p = 3.62 × 10-9).”
Claim 2 of 5SupportedA new study from The Wistar Institute found a link between the nervous system and the rapid development of neuroendocrine prostate cancer (NEPC).View evidenceHide evidence

Why this verdict

The abstract-level profile supports a link between neuronal mediators/NMU and NEPC biology: early NEPC in a mouse model showed upregulated neuronal mediators with NMU as a top candidate, and NMU/S100A9 targeting affected NEPC growth and immune features. The phrasing is hedged as a 'link,' which fits the evidence better than a definitive patient-level causal claim.

1

Study evidence

Early-stage NEPC in a transgenic mouse model is associated with increased intraprostatic Ly6G+ PMN recruitment.

“Using a transgenic mouse model, we now show that early stages of NEPC are associated with increased intraprostatic recruitment of Ly6G+ polymorphonuclear neutrophils (PMN) and reduced infiltration of CD8+ T cells.”
2

Study evidence

Early NEPC in the transgenic mouse model was associated with increased intraprostatic Ly6G+ polymorphonuclear neutrophils (PMN) and reduced CD8+ T cell infiltration.

“This coincided with expansive transcriptional changes of increased cell viability and cell migration, as well as upregulation of multiple neuronal mediators with the neuropeptide, Neuromedin U (NMU) as the top hit (Z score = 4.34; FDR < 5%; p = 3.62 × 10-9).”
Claim 3 of 5SupportedThe study found high levels of neuromedin U (NMU), a neurotransmitter, in prostate cells during the earliest phase of NEPC formation.View evidenceHide evidence

Why this verdict

The profile reports NMU upregulation in early-stage mouse NEPC tumor transcriptional profiling and high NMU expression in human prostate cancer samples across early and late stages. The abstract does not provide detailed cell-type localization, but the story's general claim of high NMU in prostate cancer/early NEPC tissue is supported at this depth.

1

Study evidence

Early-stage NEPC in a transgenic mouse model is associated with increased intraprostatic Ly6G+ PMN recruitment.

“Using a transgenic mouse model, we now show that early stages of NEPC are associated with increased intraprostatic recruitment of Ly6G+ polymorphonuclear neutrophils (PMN) and reduced infiltration of CD8+ T cells.”
2

Study evidence

Early NEPC in the transgenic mouse model was associated with increased intraprostatic Ly6G+ polymorphonuclear neutrophils (PMN) and reduced CD8+ T cell infiltration.

“This coincided with expansive transcriptional changes of increased cell viability and cell migration, as well as upregulation of multiple neuronal mediators with the neuropeptide, Neuromedin U (NMU) as the top hit (Z score = 4.34; FDR < 5%; p = 3.62 × 10-9).”
Claim 4 of 5SupportedThe article says NMU supports tumor progression by blocking the immune response and keeping T cells out of the tumor.View evidenceHide evidence

Why this verdict

The paper profile supports a mechanistic role for NMU in immunosuppression: NMU-exposed PMNs/neutrophils suppress T-cell proliferation in vitro, early mouse NEPC has reduced CD8+ T-cell infiltration, and NMU/S100A9 targeting recruits CD8+ T cells and inhibits tumor growth in vivo. The causal wording is backed by preclinical intervention and mechanistic assays, though not by patient treatment evidence.

1

Study evidence

Early-stage NEPC in a transgenic mouse model is associated with increased intraprostatic Ly6G+ PMN recruitment.

“Using a transgenic mouse model, we now show that early stages of NEPC are associated with increased intraprostatic recruitment of Ly6G+ polymorphonuclear neutrophils (PMN) and reduced infiltration of CD8+ T cells.”
2

Study evidence

Recombinant NMU exposure of primary PMNs increased PMN migration, induced inflammatory gene expression with higher S100A9 levels, and enabled suppression of T cell proliferation.

“Exposure of PMN to recombinant NMU was sufficient to stimulate cell migration, inflammatory gene expression with increased levels of the cytokine-like alarmin, S100A9”
Claim 5 of 5SupportedBy targeting NMU for destruction in a simulated microenvironment, the researchers say they could restore sensitivity to immunotherapy and allow T cells back into the tumor.View evidenceHide evidence

Why this verdict

The profile reports that genetic or pharmacologic targeting of NMU/S100A9 signaling in vivo inhibited NEPC growth, recruited tumor antigen-specific CD8+ T cells, and enhanced immune checkpoint inhibitor activity. The story's 'restore sensitivity to immunotherapy' and 'allow T cells back' framing is consistent with the paper's abstract-level interpretation, provided it is understood as preclinical mouse evidence rather than proven patient therapy.

1

Study evidence

Genetic or pharmacologic targeting of NMU/S100A9 signaling inhibited NEPC tumor growth in vivo.

“Genetic or pharmacological targeting of NMU/S100A9 signaling inhibited NEPC growth, reinvigorated an intratumoral immune microenvironment via recruitment of tumor antigen-specific CD8+ T cells with 'stem-like' (TCF1+/PD1+) and cytotoxic (GrzB+/KLRG1+) properties and enhanced the activity of therapeutic immune checkpoint inhibition, in vivo.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Human prostate cancer sample analysis found NMU highly expressed across early and late disease and preferentially associated with AR-negative/neuroendocrine-positive metastatic disease.

    The story focuses on mouse and simulated/preclinical findings and does not clearly report the human biospecimen association with AR-/NE+ metastatic disease.

    From secondary_data

  • The abstract does not provide many robustness details, including sample sizes, effect magnitudes, full statistical methods, exact assay formats, drug identities/doses, or checkpoint-inhibitor regimen.

    The story does not mention these abstract-level limitations. They are important for judging robustness, although they do not negate the main preclinical findings.

    From transgenic mouse in vivo profiling (early-stage NEPC); Transgenic NEPC mouse model; bulk tissue transcriptomic profiling

6 things the story did carry across
  • Early mouse NEPC is associated with increased Ly6G+ polymorphonuclear neutrophils and reduced CD8+ T-cell infiltration in the prostate/tumor microenvironment.
  • Mouse tumor transcriptional profiling identified upregulated neuronal mediators, with NMU as the top candidate in early NEPC.
  • NMU directly reprograms PMN/neutrophil behavior in vitro, increasing migration and inflammatory programs including S100A9 and enabling suppression of T-cell proliferation.
  • Genetic or pharmacologic targeting of NMU/S100A9 signaling in vivo inhibited NEPC growth, recruited tumor antigen-specific CD8+ T cells, and enhanced immune checkpoint inhibitor activity.
  • The evidence is preclinical, relying heavily on a transgenic mouse model and in vitro/ex vivo mechanistic assays; it does not demonstrate clinical efficacy in patients.
  • The human-sample NMU association is observational/specimen-based and does not itself establish that NMU causes human NEPC progression or treatment resistance.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

6

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalGenetic or pharmacologic targeting of NMU/S100A9 signaling inhibits NEPC growth, reshapes the intratumoral immune microenvironment (tumor antigen-specific CD8+ T-cell recruitment/phenotypes), and enhances immune checkpoint inhibitor activity in vivo.in vivo animal interventionExpand

In plain English

In a transgenic mouse NEPC model, genetic or pharmacologic targeting of NMU/S100A9 signaling reduced tumor growth, increased recruitment of tumor antigen-specific CD8+ T cells with stem-like (TCF1+/PD1+) and cytotoxic (GrzB+/KLRG1+) phenotypes, and improved the activity of therapeutic immune checkpoint inhibition in vivo. Details on interventions, effect sizes, and statistical measures are not reported in the abstract.

Key findings

  • Genetic or pharmacologic targeting of NMU/S100A9 signaling inhibited NEPC tumor growth in vivo.
  • Targeting NMU/S100A9 reinvigorated the intratumoral immune microenvironment by recruiting tumor antigen-specific CD8+ T cells with 'stem-like' (TCF1+/PD1+) and cytotoxic (GrzB+/KLRG1+) properties.
“Genetic or pharmacological targeting of NMU/S100A9 signaling inhibited NEPC growth, reinvigorated an intratumoral immune microenvironment via recruitment of tumor antigen-specific CD8+ T cells with 'stem-like' (TCF1+/PD1+) and cytotoxic (GrzB+/KLRG1+) properties and enhanced the activity of therapeutic immune checkpoint inhibition, in vivo.”
What this piece can’t prove
  • Summary is based on abstract text only; the abstract lacks experimental details (sample sizes, replicates, statistical tests, exact effect sizes, and p-values) necessary to appraise robustness.

4 further details could not be confirmed from the summary.

2in vivo animalIn a transgenic mouse model of NEPC, early disease is associated with altered intraprostatic immune composition (↑Ly6G+ PMN; ↓CD8+ T cells) and transcriptional upregulation of neuronal mediators, with Neuromedin U (NMU) as a top candidate.transgenic mouse in vivo profiling (early-stage NEPC)Expand

In plain English

In a transgenic mouse model of neuroendocrine prostate cancer (NEPC), early-stage disease shows altered intraprostatic immune composition with increased Ly6G+ polymorphonuclear neutrophils (PMN) and reduced CD8+ T-cell infiltration; concurrent tumor transcriptional changes include upregulation of neuronal mediators with Neuromedin U (NMU) as the top hit (Z = 4.34; FDR < 5%; p = 3.62 × 10-9).

Key findings

  • Early-stage NEPC in a transgenic mouse model is associated with increased intraprostatic Ly6G+ PMN recruitment.
  • Early-stage NEPC in a transgenic mouse model is associated with reduced intraprostatic CD8+ T-cell infiltration.
“Using a transgenic mouse model, we now show that early stages of NEPC are associated with increased intraprostatic recruitment of Ly6G+ polymorphonuclear neutrophils (PMN) and reduced infiltration of CD8+ T cells.”
What this piece can’t prove
  • Findings are from a transgenic mouse model and may not directly generalize to human disease without further validation (as presented in this unit).

2 further details could not be confirmed from the summary.

3in vivo animalIn a transgenic mouse model of NEPC, early disease is associated with altered intraprostatic immune composition (↑Ly6G+ PMN; ↓CD8+ T cells) and transcriptional upregulation of neuronal mediators, with Neuromedin U (NMU) as a top candidate.Transgenic NEPC mouse model; bulk tissue transcriptomic profilingExpand

In plain English

In a transgenic mouse model of neuroendocrine prostate cancer (NEPC), early disease stages showed altered intraprostatic immune composition (increased Ly6G+ polymorphonuclear neutrophils; decreased CD8+ T cells). Bulk transcriptional profiling of mouse tumors revealed upregulation of multiple neuronal mediators, with the neuropeptide Neuromedin U (NMU) identified as the top hit (Z score = 4.34; FDR < 5%; p = 3.62 × 10^-9).

Key findings

  • Early NEPC in the transgenic mouse model was associated with increased intraprostatic Ly6G+ polymorphonuclear neutrophils (PMN) and reduced CD8+ T cell infiltration.
  • Bulk transcriptional profiling identified upregulation of multiple neuronal mediators in mouse tumors, with Neuromedin U (NMU) as the top hit.Z = 4.34; p = 3.62 × 10^-9; FDR < 5%
“This coincided with expansive transcriptional changes of increased cell viability and cell migration, as well as upregulation of multiple neuronal mediators with the neuropeptide, Neuromedin U (NMU) as the top hit (Z score = 4.34; FDR < 5%; p = 3.62 × 10-9).”
What this piece can’t prove
  • Findings are from a transgenic mouse model; this unit does not provide direct evidence on human tissues (outside the scope of this appraisal unit).

2 further details could not be confirmed from the summary.

4secondary dataIn human prostate cancer samples, NMU expression is elevated across stages and preferentially associates with AR-/NE+ metastatic disease.secondary dataExpand

In plain English

Analysis of a large cohort of human prostate cancer samples found NMU expression to be high across early and late stage disease and to preferentially segregate with AR-negative, neuroendocrine-positive (AR-/NE+) metastatic cases, based on the abstract's report.

Key findings

  • NMU expression is elevated across early and late stage human prostate cancers and preferentially segregates with AR-/NE+ metastatic samples.
“Analysis of a large cohort of human patient samples revealed that NMU was highly expressed in early and late stage prostate cancer, preferentially segregating with AR-/NE+ metastases.”
What this piece can’t prove
  • Unclear whether expression was measured at RNA or protein level and whether findings were adjusted for potential confounders.

2 further details could not be confirmed from the summary.

5in vitroNMU directly reprograms neutrophil/PMN behavior toward migration and immunosuppressive, inflammatory programs (e.g., S100A9 upregulation) that suppress T-cell proliferation.in vitro PMN stimulationExpand

In plain English

In vitro exposure of primary PMNs to recombinant Neuromedin U (NMU) induced PMN migration, upregulated inflammatory gene expression including increased levels of the alarmin S100A9, and conferred suppression of T‑cell proliferation, consistent with NMU-driven reprogramming of neutrophil/PMN toward a migratory, immunosuppressive inflammatory phenotype.

Key findings

  • Recombinant NMU exposure of primary PMNs increased PMN migration, induced inflammatory gene expression with higher S100A9 levels, and enabled suppression of T cell proliferation.
“Exposure of PMN to recombinant NMU was sufficient to stimulate cell migration, inflammatory gene expression with increased levels of the cytokine-like alarmin, S100A9”
What this piece can’t prove
  • Abstract does not report quantitative effect sizes, replicate numbers, or detailed assay parameters for the migration, expression, or T cell suppression assays.

1 further detail could not be confirmed from the summary.

6in vitroNMU directly reprograms neutrophil/PMN behavior toward migration and immunosuppressive, inflammatory programs (e.g., S100A9 upregulation) that suppress T-cell proliferation.Expand

In plain English

The abstract reports that in vitro exposure of polymorphonuclear neutrophils (PMN) to recombinant Neuromedin U (NMU) rendered PMN able to suppress T-cell proliferation in a co-culture or conditioned-media proliferation assay; NMU-treated PMN also showed inflammatory gene expression changes including increased S100A9.

Key findings

  • Exposure of PMN to recombinant NMU in vitro was reported to suppress T-cell proliferation; NMU-treated PMN also showed inflammatory gene induction including increased S100A9.
“and suppression of T cell proliferation.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 38 candidate papers

Candidate

Author response for "Transport characteristics of 2DHG in p-GaN/AlGaN/GaN heterojunction: impact of Mg dopant activation"

2026 · Crossref

Source (opens in a new tab)
Candidate

Author Reply to Peer Reviews of Human Oncogene EWS::FLI1 Functions as a Pioneer Factor in Saccharomyces cerevisiae

2026 · Crossref

Source (opens in a new tab)

And 32 more candidates considered.